NLRP3 and COVID-19: Colchicine may also be utilized to treat COVID-19 as a major inhibitor of NLRP3 inflammasomes, and, based on these perspectives, several RCTs are being conducted to assess the potential of colchicine to improve outcomes in patients with COVID-19.